- Allergic rhinitis affects approximately 30% of US adults and 40% of children
- Seasonal allergic rhinitis is triggered by outdoor pollen — trees, grasses, and weeds
- Perennial allergic rhinitis is triggered by year-round allergens — dust mites, pet dander, mold
- The immune mechanism is IgE-mediated — your body produces antibodies to harmless substances
- Treatment ranges from antihistamines and nasal sprays to immunotherapy that changes the immune response
What Is Allergic Rhinitis?
Allergic rhinitis is the clinical term for an immune-mediated inflammation of the nasal mucosa triggered by allergen exposure. It's classified as a type I hypersensitivity reaction — meaning it's driven by IgE antibodies that cause rapid mast cell degranulation when they encounter specific allergens, releasing histamine and other inflammatory mediators that produce the characteristic symptoms: sneezing, congestion, runny nose, and itchy eyes.
"Hay fever" is the common name — historically misleading because hay is rarely the trigger and fever never occurs. The ARIA (Allergic Rhinitis and Its Impact on Asthma) clinical guidelines categorize allergic rhinitis into seasonal and perennial forms based on trigger type, with further classification by severity and impact on quality of life.
Seasonal vs Perennial Allergic Rhinitis
Seasonal Allergic Rhinitis
Triggered by outdoor airborne allergens that follow seasonal patterns — primarily tree pollen (spring), grass pollen (summer), and weed pollen (late summer/fall). Symptoms correlate precisely with the regional pollen calendar. Patients are typically symptom-free between seasons. This is the form most people associate with "hay fever" or "spring allergies."
Perennial Allergic Rhinitis
Triggered by year-round allergens — primarily house dust mites, cockroach allergen, pet dander (cat Fel d 1, dog Can f 1), and indoor mold. Symptoms are present throughout the year, often worse in the morning (dust mites disturbed from bedding), or correlated with indoor environments. Patients often report feeling worse at home and better when traveling.
Mixed Allergic Rhinitis
Many patients have both seasonal and perennial sensitizations — experiencing year-round symptoms from perennial allergens with seasonal flares from pollen exposures. This combined picture is common in clinical practice and often requires addressing both indoor and outdoor exposures as part of management.
Local Allergic Rhinitis
A less commonly recognized form where IgE production occurs locally in nasal tissue without detectable systemic IgE. Standard skin prick and blood tests may be negative while the patient has genuine allergic inflammation. Diagnosis requires specialized nasal provocation testing. Estimated to affect 25-40% of patients with negative standard tests but allergic symptoms.
The Immune Mechanism
Allergic rhinitis develops in two phases. Sensitization: Initial exposure to an allergen leads to production of allergen-specific IgE antibodies that bind to mast cells and basophils in nasal mucosa. No symptoms occur — you're building the immune apparatus for future reactions. Elicitation: Subsequent exposures cause IgE-bound mast cells to degranulate immediately, releasing histamine, leukotrienes, prostaglandins, and other mediators that produce the rapid allergic response (sneezing, itching, watery discharge). A late-phase response occurs 4-12 hours later driven by eosinophil infiltration, producing the congestion and fatigue that persist beyond the immediate reaction.
Diagnosis
Allergic rhinitis is diagnosed clinically based on symptom history and physical examination, and confirmed by allergy testing. Skin prick testing (SPT) is the standard — small amounts of allergen extracts are introduced to the skin surface, and wheal formation indicates IgE-mediated sensitization. Specific IgE blood testing (ImmunoCAP) is an alternative for patients unable to undergo skin testing. Both tests identify which specific allergens are driving the patient's symptoms.
Treatment Hierarchy
| Treatment Type | How It Works | Appropriate For |
|---|---|---|
| Allergen avoidance | Reducing exposure reduces immune stimulus | All patients — foundational |
| Intranasal corticosteroids | Reduce mucosal inflammation — most effective pharmacotherapy | Moderate-severe symptoms |
| Second-gen antihistamines | Block H1 receptors — fexofenadine, loratadine, cetirizine | Mild-moderate, breakthrough |
| Nasal antihistamines | Faster onset than oral; direct mucosal action | Rapid symptom relief |
| Leukotriene modifiers | Block inflammatory leukotriene pathways | Co-morbid asthma |
| Immunotherapy (SCIT/SLIT) | Retrain immune tolerance — addresses underlying sensitization | Moderate-severe, 3-5 year commitment |
Manage your allergic rhinitis with daily intelligence.
Anthos gives you personalized daily readings, species-level pollen data, and your personal threshold — the daily intelligence layer that makes every other allergy intervention more effective.
Download on the App StoreRelated Guides
Anthos provides general wellness information only. Nothing in this article constitutes medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before making health decisions.